Published Date: September 13, 2024
Application Deadline: October 31, 2024
Grant Categories & Scope
The Osteosarcoma Institute offers grants in the following categories:
- Clinical Trials: Up to $800,000 over 2-3 years for Phase I/II or Phase II trials aimed at improving event free survival in relapsed/refractory osteosarcoma.
- Correlative Science: $200,000 – $500,000 over 2 years for studies generating data to improve understanding and treatment of recurrent and metastatic osteosarcoma.
- Preclinical/Translational: Up to $500,000 for 2 years focusing on identifying biological dependencies in osteosarcoma.
- High-Risk/High-Impact: $25,000 – $125,000 over 1 year for bold, innovative research with potential high impact on osteosarcoma treatment.
Eligibility Criteria
To be eligible, applicants must meet the following criteria:
- Funds are granted to nonprofit/charitable institutions or organizations.
- The grantee organization does not need to be based in the United States.
- Applicants must hold an MD, PhD, MD/PhD, or equivalent and be faculty members or equivalent at an academic institution.
- Applicants are not required to be U.S. citizens.
- Applicants should have a track record of publication and funding productivity.
- The proposed project must represent a new research direction, not a continuation of ongoing funded research.
Additional Information
Selected grantees will allow OSI to publicize the grant for fundraising purposes, including a five-minute video discussing the research project and related photos.
For more information and to apply, visit the Osteosarcoma Institute's Grant Program 2024.
.jpg)
.jpg)
0 Comments